SR9011 Guide: Dosage, Side Effects and Benefits

Short answer: SR9011 is an experimental REV-ERB agonist (a body-clock drug), not a SARM and not the same as Stenabolic (SR9009). It has only been studied in mice and cells: injected into mice, it raised energy use, lowered fat mass and changed sleep and activity patterns (Solt 2012). There is no researched human dosage; users report 10–30 mg a day split into several doses. Human side effects are not established, and it is banned in sport.

What is SR9011

SR9011 is a synthetic agonist of REV-ERB-alpha and REV-ERB-beta, nuclear receptors that help run the circadian clock and control metabolic genes in the liver, skeletal muscle and fat tissue. It was described in 2012 by researchers at the Scripps Research Institute together with its sister compound SR9009 (Solt 2012). The older version of this article called SR9011 “also known as Stenabolic” and a SARM; neither is correct. Stenabolic is SR9009, and neither compound acts on the androgen receptor.

The nickname “exercise in a bottle” comes from the mouse results below. For legality, sport and an overview, see our SR9011 review.

The Study & Development

The research behind SR9011 is all preclinical:

The older version of this article quoted a 50% increase in running capacity and 10–15 lb of fat loss in “studies”. We found no study with those numbers for SR9011, and no study in people at all.

SR9011 Benefits

• Fat loss (mice): lower fat mass with longer treatment; food intake unchanged (Solt 2012). Not shown in people.
• Energy use (mice): about 5% higher oxygen use (Solt 2012).
• Endurance: activating REV-ERB-alpha increased exercise capacity in mice (Woldt 2013); not tested with SR9011 in people.
• Anxiety (mice): less anxiety-like behavior with REV-ERB agonists (Banerjee 2014).
• Muscle growth: not shown in any study we found.
• Cholesterol and liver fat: lipid improvements were reported in obese mice given SR9009 (Solt 2012); not measured in people.

SR9011 Side Effects

Human side effects are not established, because no one has taken SR9011 in a study. What the research and user reports point to:

• Sleep problems: users report insomnia; in mice, REV-ERB agonists increased wakefulness and cut REM and deep sleep (Banerjee 2014). The old claim that “4 out of 24 people” had insomnia had no source.
• Unknown off-target effects: the sister compound changed cells that lacked its target (Dierickx 2019).
• Liver: no SR9011 data, but SR9009 has been linked to acute liver failure needing a transplant in a 17-year-old (Shams Bin Shaheen 2026) and to liver injury in a 40-year-old man (Govil 2025).
• Absorption: claims about poor oral bioavailability, and about skin products that fix it, have not been tested.

SR9011 For Women

There are no data on SR9011 in women. The old claim that it works the same in men and women “without the potential side effects” of steroids was not based on any study, and has been removed. Since SR9011 does not act on the androgen receptor, masculinizing effects would not be expected, but its other effects, including on sleep and the liver, are simply unknown.

Dosage

There is no researched human dose. In mice, effective doses were around 50–100 mg per kg of body weight by injection, which cannot be converted into a safe human dose (Solt 2012). The half-life in people is not established; the old figure of about four hours had no source.

These are what users describe, not tested or recommended doses. Users avoid evening doses because of sleep problems. For the sister compound, see SR9009 dosage.

Bulking & Cutting Stacks:

No SR9011 stack has been studied. Users describe pairing it with MK-677 or LGD-4033 on a bulk and with RAD-140, ostarine or AC-262 on a cut. The partner compounds have their own documented effects: ostarine and LGD-4033 lowered testosterone and HDL in trials (Dalton 2011, Basaria 2013), MK-677 raised appetite and blood sugar, RAD-140 raised liver enzymes in most patients in its trial (LoRusso 2022), and AC-262 has only rat data. Check any combination with the stack checker and read RAD-140 stacks.

Conclusion:

SR9011 is a research tool for the body clock with interesting mouse results (more energy use, less fat, altered sleep, anti-cancer effects in cells) and no human data. Its dose, half-life, absorption and side effects in people are unknown, and its sister compound SR9009 has been linked to serious liver injury. WADA bans SR9011 at all times (WADA 2026), and in Australia it is Schedule 4 with possession controls (Poisons Standard). Compare it with better-studied compounds in the SARMs database.